Targeting the Multi-Factorial Root Causes of CVD

We are a Michigan bio-sciences group that shares a scientifically supported hypothesis that cholesterol is not the cause of Atherosclerosis and that there is no such thing as ‘bad’ cholesterol as it is essential for overall health and well-being.

We're proud to introduce first-in-class diagnostic panels (GlycoCardia) and triple compound oral therapy (Embotricin) innovations that may prove to be a profound breakthrough in the pursuit to predict, prevent and cure Cardiovascular Disease (CVD). 
 

36 Month Target

In-human, proof of principle against hypertension, heart failure and coronary heart disease.  

Offerings and IP Summary

"Historical development of antibiotics targeting microorganisms led to a cure of infectious disease. An equivalent approach is to target the endothelial glycocalyx to cure CVD by an anti-embolic™ mechanism."

Dr. Joe Tunac

Primary Offerings

IP Matter Description

 

Embotricin

A rationally synthesized,  triple compound,  oral therapy with unique mechanisms of action targeting the root causes of CVD/CHD proven to prevent and reverse arterial plaques, the hallmark of CVD.

 

GlycoCardia™

Diagnostic panels that provide specific information on the associated pathology and risk factors of multiple CVD diseases and stages of same. 

Methods and Composites for reversing disruption of the Glycocalyx, inflammation and oxidative damage.

Compounds against Vascular Disease

Animal model for cardiovascular disease and inflammation

Biomarkers of Cardiovascular Disease 

Biomarkers for Clotting

Recent News

Recent News

    Team Profiles

Dr. Joe Tunac
President & Chairman
Michael Brennan
Chief Executive Officer
Brett Homovec
Chief Financial Officer
Show More

Connect With Us

 

CONTACT FORM

FILE SHARE

© 2018 All Copyrights Reserved, Arterez, LLC

Brett Homovec

Chief Financial Officer